Effect of Allopurinol and Febuxostat on Urinary 2,8-Dihydroxyadenine Excretion

Phase 4 Completed 9 enrolled Landspitali University Hospital Mayo Clinic · collab National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collab

NaSingle-groupOpen-labelTreatment

Summary

This exploratory pilot study was an open-label, crossover, single-center and non-randomized clinical trial designed to compare the effect of the standardly employed doses of allopurinol (400 mg/day) and febuxostat (80 mg/day) on the urinary 2,8-dihydroxyadenine (DHA) excretion in patients with adenine phosphoribosyltransferase (APRT) deficiency.

Timeline

Start: 2013-05
Primary completion: 2015-05
Completion: 2015-05

Publications

Results Runolfsdottir HL, Palsson R, Agustsdottir IM, Indridason OS, Edvardsson VO. Kidney Disease in Adenine Phosphoribosyltransferase Deficiency. Am J Kidney Dis. 2016 Mar;67(3):431-8. doi: 10.1053/j.ajkd.2015.10.023. Epub 2015 Dec 25.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Allopurinol	Small molecule	400 mg	—
Subject	Febuxostat	Small molecule	80 mg	—

Effect of Allopurinol and Febuxostat on Urinary 2,8-Dihydroxyadenine Excretion

Summary

Timeline

Publications

Drugs

Indications